partnering

News

Sanofi buys into Teva’s anti-TL1A therapy for IBD

In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva

News

Sanofi partners J&J on E. coli vaccine

Sanofi is paying $175 million upfront to claim a share of an experimental vaccine developed by Johnson & Johnson’s pharma unit Janssen that aims to tackle a major caus

News

Biogen shuts digital health unit and exits Apple alliance

Biogen has decided to close down its digital health unit, formed just two years ago, as part of a major cost-reduction drive that has already claimed thousands of jobs.

News

Takeda joins PIKfyve ALS push with AcuraStem deal

Takeda has bolstered its neuroscience pipeline by licensing drug candidates from California biotech AcuraStem targeting PIKfyve, which is gathering attention as a drug tar

News

Boehringer backs NHS trust programme for diabetics

An alliance between German pharma group Boehringer Ingelheim and an NHS trust in the UK has been launched with the aim of reducing recurring heart attacks in people with d

News

Roche inks pipeline deals with Orionis, PeptiDream

Roche has bolstered its R&D pipeline in oncology and neuroscience with a pair of partnerships with Orionis Biosciences and PeptiDream, parting with upfront cash of $87

Sanofi buys into Teva’s anti-TL1A therapy for IBD

Sanofi partners J&J on E. coli vaccine

Biogen shuts digital health unit and exits Apple alliance

Takeda joins PIKfyve ALS push with AcuraStem deal

Boehringer backs NHS trust programme for diabetics

Roche inks pipeline deals with Orionis, PeptiDream

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

partnering

Editor's Picks